Axel Merseburger, ESMO 2019 – Advances in metastatic hormone-sensitive prostate cancer
Our Editor-in-Chief, Axel Merseberger (University Hospital Schleswig-Holstein), joined us at ESMO 2019 to discuss current limitations in the treatment of metastatic hormone-sensitive prostate cancer, use of antiandrogen agents, and what the future may hold.
1. What are the limitations of the current standard of care for metastatic hormone-sensitive prostate cancer (mHSPC)? (0:05)
2. What have recent clinical studies taught us about the optimum use of the antiandrogen agents enzalutamide, abiraterone acetate and apalutamide in the treatment of men with mHSPC? (0:40)
3. What factors should be considered when making treatment decisions for mHSPC? (1:22)
4. What is the safety profile of the anti-androgen agents? (2:02)
5. What future role do you see for chemotherapy in the treatment of mHSPC? (2:52)
6. What do you expect to be the next major breakthrough in the treatment of mHSPC? (3:49)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Axel Merseberger has nothing to disclose in relation to this video.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Prostate Cancer
Fred Saad, ESMO 2022: Highlights in prostate cancer – Phase 3 trials in the STAMPEDE platform protocol
Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss clinical trial highlights in prostate cancer presented at EMSO 2022. He highlights the results from one of the phase 3 STAMPEDE trials, investigating combination abiraterone and enzalutamide or abiraterone and prednisolone, for metastatic hormone sensitive prostate cancer (mHSPC), […]
Fred Saad, ESMO 2022: Phase 3 PROpel trial of abiraterone and olaparib for patients with prostate cancer – Biomarker analysis and updated results
In the PROpel trial, abiraterone and olaparib significantly prolonged radiographic progression free survival in patients with metastatic castration-resistant prostate cancer. Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss the biomarker analysis from the primary analysis, and updated overall survival and safety data. The abstract entitled ‘Biomarker […]
Axel Merseburger, ASCO 2022: Highlights in prostate cancer clinical trials – Phase 3 SHR3680 trial, ENZAMET trial, MAGNITUDE trial, PROPEL trial, phase 2 lutetium 177 trial, VISION trial
ASCO 2022 showcased many important studies in prostate cancer. Prof. Axel Merseburger (Department of Urology, University of Lubeck, Germany), touchONCOLOGY’s Editor-in-Chief, joins us to share his highlights. In this interview he discusses: the phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy in patients with prostate cancer (0:40); the interim overall […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!